8NE:FRA
Lisata Therapeutics, Inc.
€ 0.95
arrow_upward
+1.06%(+0.0100) 1D
10-р сарын 7, 08:04:01 (GMT+2) · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 8NE...
Open
€ 0.95
High
€ 0.95
Low
€ 0.95
Mkt. cap
12.80 сая
Avg. vol.
0.00
Volume
0.00
52-wk high
€ 4.34
52-wk low
€ 0.74
No. of employees
21
Open
€ 0.95
High
€ 0.95
Low
€ 0.95
Mkt. cap
12.80 сая
Avg. vol.
0.00
Volume
0.00
52-wk high
€ 4.34
52-wk low
€ 0.74
No. of employees
21
News stories
From web sources and news partners
Yahoo Finance
·
2 өдрийн өмнө
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, Нью Жерси, Америкийн Нэгдсэн Улс
Sector-
Websitelisata.com